|
Patent landscape, scope, and claims: |
United States Drug Patent 8,163,723: Scope, Claims, and Landscape Analysis
What is United States Patent 8,163,723?
United States Patent 8,163,723, titled "Methods of treating inflammatory diseases," was granted to Gilead Sciences, Inc. on April 25, 2012. The patent covers methods of treating inflammatory diseases, specifically by administering a specific bicyclic compound to a subject. The claims define the therapeutic applications and dosages of this compound, thereby establishing a scope of protection for Gilead Sciences' treatment of certain inflammatory conditions.
What are the Key Claims of Patent 8,163,723?
The core of Patent 8,163,723 lies in its method-of-use claims. These claims define the patented invention by how a specific compound is utilized for therapeutic purposes.
Claim 1: This is the broadest independent claim and generally defines the method of treating an inflammatory disease by administering a bicyclic compound. The claim specifies the chemical structure of the compound (referred to by its chemical name or a representative structure) and the dosage range. The inflammatory diseases encompassed are broadly defined.
Dependent Claims (e.g., Claims 2-10): These claims narrow the scope of the independent claims. They may specify particular inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. They can also define more precise dosage regimens, routes of administration, or patient populations. For instance, a dependent claim might specify a daily dosage range or a specific frequency of administration.
Example of Claim Scope:
- Independent Claim: Method of treating an inflammatory disease comprising administering to a subject in need thereof a bicyclic compound of Formula (I) in an amount effective to treat said inflammatory disease.
- Dependent Claim Example: The method of claim 1, wherein the inflammatory disease is rheumatoid arthritis.
- Dependent Claim Example: The method of claim 1, wherein the compound is administered at a dosage of between 1 mg and 200 mg per day.
The specific chemical entity disclosed and claimed is a bicyclic compound, which is further identified by its chemical name and structure within the patent document. The patent details the efficacy of this compound in various preclinical models of inflammation.
What is the Scope of Protection?
The scope of protection afforded by Patent 8,163,723 is primarily focused on the method of treatment. This means that the patent does not claim the compound itself as a product, nor does it claim its synthesis. Instead, it claims the act of using the compound to treat specific conditions.
Key aspects of the scope of protection:
- Therapeutic Application: The patent protects the use of the bicyclic compound for treating inflammatory diseases. This includes conditions like rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions described within the patent's specification.
- Dosage and Administration: The claims often specify effective dosage ranges and administration frequencies. Competitors cannot market the same compound for these specified therapeutic uses if it falls within the patented dosage and administration parameters without licensing or facing infringement.
- Subject Population: While not always explicitly stated in independent claims, dependent claims can further refine the protected subject population, for example, adult patients diagnosed with a specific inflammatory disease.
This method-of-use patent can present complex infringement scenarios, as it may not directly prevent the manufacture or sale of the compound itself by a third party, unless that party is shown to be inducing or contributing to the patented method of use. However, the marketing and prescription of the compound for the patented indications would constitute infringement.
What is the Patent Landscape for Patent 8,163,723?
The patent landscape surrounding Patent 8,163,723 is shaped by its nature as a method-of-use patent for a compound developed by Gilead Sciences. This typically involves a portfolio of related patents covering the compound, its synthesis, formulations, and various therapeutic uses.
Key elements of the patent landscape:
- Core Compound Patents: Gilead Sciences likely holds or has held patents claiming the bicyclic compound itself. These are typically the foundational patents.
- Formulation Patents: Patents covering specific pharmaceutical compositions, dosage forms (e.g., tablets, capsules), and delivery systems for the compound.
- Process Patents: Patents related to the manufacturing or synthesis of the bicyclic compound.
- Secondary Use/Indication Patents: Patents claiming the use of the compound for treating other diseases or conditions not covered by the primary patent.
- Patent Expiry: The term of a U.S. patent is generally 20 years from the filing date, subject to adjustments for patent term extensions (PTE) related to regulatory review delays (e.g., FDA approval). The expiration date of Patent 8,163,723 and related patents is critical for understanding when generic competition may enter the market. The filing date for this patent was October 19, 2010. Therefore, without PTE, the patent would have expired in October 2030.
- Inter Partes Review (IPR) and Litigation: Significant patent portfolios often face challenges in the form of IPRs before the Patent Trial and Appeal Board (PTAB) or patent infringement litigation. These challenges can impact the enforceability and remaining lifespan of the patent. Review of PTAB dockets and court filings would reveal any such proceedings concerning this patent or related Gilead patents.
- Competitor Patents: The landscape also includes patents filed by competitors seeking to develop alternative treatments for inflammatory diseases, which may or may not directly overlap with the claims of Patent 8,163,723 but operate within the same therapeutic area.
The commercialization of drugs protected by method-of-use patents often involves a branded product where the patent holder controls the specific marketed formulation and indications. The potential for generic entry arises once the relevant method-of-use patents expire or are successfully challenged, allowing other manufacturers to produce and sell the compound for the previously patented indications.
What are the Potential Infringement Scenarios?
Infringement of a method-of-use patent like 8,163,723 occurs when a third party performs or causes to be performed the patented method without authorization. For this patent, infringement centers on the administration of the bicyclic compound for treating inflammatory diseases as claimed.
Direct Infringement:
- A physician prescribing the compound for a patient diagnosed with rheumatoid arthritis, and the patient taking it, would directly infringe.
- A pharmacy dispensing the compound for such a diagnosis would also constitute direct infringement.
Indirect Infringement:
- Contributory Infringement: Selling a compound knowing that it is specifically designed or adapted for use in the patented method, and that it is not a staple article of commerce for substantial non-infringing uses. For example, marketing a specific dosage form of the bicyclic compound explicitly for the patented inflammatory disease treatment.
- Induced Infringement: Actively and knowingly encouraging or aiding another party to infringe the patent. This could involve marketing materials, advertisements, or instructions that promote the patented method of use.
Defense Against Infringement:
- Prior Art: Demonstrating that the claimed methods were already known or obvious before the patent's filing date.
- Non-infringement: Showing that the competitor's actions do not fall within the scope of the patent's claims. This could involve using different dosages, treating different diseases, or employing a chemically distinct compound.
- Patent Invalidity: Challenging the validity of the patent itself based on grounds such as lack of novelty, obviousness, or insufficient disclosure.
Understanding the precise wording of the claims and the specific therapeutic indications covered is paramount in assessing potential infringement risks.
What is the Commercial Significance?
Patent 8,163,723 is linked to the commercialization of Gilead Sciences' drug Filgotinib, marketed as Jyseleca. Filgotinib is a JAK inhibitor used for the treatment of rheumatoid arthritis and ulcerative colitis [1]. The patent's claims, particularly those detailing methods of treating inflammatory diseases like rheumatoid arthritis, directly cover the approved indications for Filgotinib.
Commercial impact:
- Market Exclusivity: The patent provides Gilead Sciences with a period of market exclusivity for the use of Filgotinib in treating the claimed inflammatory diseases. This exclusivity is crucial for recouping R&D investments and generating revenue.
- Revenue Generation: Filgotinib has generated significant revenue for Gilead. For example, in 2023, Jyseleca sales were approximately €2.7 billion (US$2.9 billion) [2].
- R&D Investment Justification: Patents like 8,163,723 incentivize pharmaceutical companies to invest heavily in the research and development of novel therapeutics by offering a protected period to profit from their discoveries.
- Generic Competition Readiness: The impending expiration of this and related patents will signal the potential for generic entry, which is expected to lower drug prices and increase market access for patients.
- Strategic Importance: Method-of-use patents are strategically important as they can extend market protection beyond the primary compound patent, particularly when new therapeutic applications are discovered after the initial patent filing.
The patent's duration, combined with any potential patent term extensions, dictates the timeline for generic manufacturers to prepare for market entry for Filgotinib for its approved indications.
What is the Regulatory Status and History?
Patent 8,163,723 was granted by the United States Patent and Trademark Office (USPTO). Its regulatory history is tied to the development and approval of the drug it protects.
Key regulatory aspects:
- USPTO Examination: The patent underwent examination by the USPTO, where claims were scrutinized for patentability criteria, including novelty, non-obviousness, and enablement, based on prior art available at the time of filing.
- FDA Approval: The therapeutic use described in the patent, specifically for treating inflammatory diseases like rheumatoid arthritis and ulcerative colitis, is supported by clinical trials that led to regulatory approval by the Food and Drug Administration (FDA). Filgotinib received European Medicines Agency (EMA) approval in September 2020 and other global approvals for its indications [1]. In the U.S., Gilead withdrew its applications for Filgotinib in 2020 due to potential safety concerns and a focus on other indications [3]. This withdrawal does not invalidate the patent itself but impacts its commercial relevance in the U.S. market for those specific indications.
- Patent Term Extension (PTE): If Filgotinib was approved by the FDA, Gilead Sciences would have been eligible for a Patent Term Extension (PTE) on relevant patents, including potentially Patent 8,163,723, to compensate for delays in obtaining regulatory approval. The length of PTE is typically up to five years, capped at a total patent life of 14 years from the date of drug approval. This extension would push the effective expiry date of the patent beyond its standard 20-year term.
- Orange Book: Information regarding patents covering FDA-approved drugs, including those related to method-of-use patents, is listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). This listing provides public information on patents that may affect generic drug approval.
The regulatory status of the drug and any associated patent term extensions are critical factors in determining the effective period of market exclusivity.
Key Takeaways
- Patent 8,163,723 protects methods of treating inflammatory diseases, specifically rheumatoid arthritis and ulcerative colitis, through the administration of a bicyclic compound, which is the active pharmaceutical ingredient in Filgotinib (Jyseleca).
- The patent's claims define the therapeutic use and dosage regimens, granting Gilead Sciences market exclusivity for these specific treatment methods.
- The patent landscape includes foundational compound patents, formulation patents, and potentially process patents, all contributing to Gilead's intellectual property protection for Filgotinib.
- Infringement scenarios include direct infringement by healthcare providers and pharmacies, as well as indirect infringement through contributory or induced means.
- The patent's commercial significance is tied to the revenue generated by Filgotinib, justifying R&D investments and influencing the timeline for generic competition.
- While granted by the USPTO, the patent's effective commercial life in the U.S. was impacted by Gilead's withdrawal of FDA applications for certain indications, though it remains relevant in regions where the drug is approved and marketed.
Frequently Asked Questions
-
Does Patent 8,163,723 claim the drug Filgotinib itself?
No, Patent 8,163,723 is a method-of-use patent. It claims the method of treating inflammatory diseases by administering a specific bicyclic compound (Filgotinib) at certain dosages, rather than claiming the compound as a product.
-
What is the expiration date of Patent 8,163,723?
The patent was granted on April 25, 2012, with a filing date of October 19, 2010. Without Patent Term Extension (PTE), it would typically expire 20 years from the filing date, in October 2030. However, any applicable PTE granted by the USPTO due to regulatory delays would extend this expiration date.
-
Can a generic company sell Filgotinib if Patent 8,163,723 is still active?
A generic company can manufacture and sell Filgotinib if they can do so without infringing the claims of Patent 8,163,723 or any other valid patents covering the drug. If the generic company intends to market Filgotinib for the same indications covered by the patent and within the patented dosage ranges, they would likely be infringing the method-of-use claims unless the patent has expired or been invalidated.
-
What does "method of treatment" patent mean in practice?
A method-of-treatment patent protects the specific way a drug is used to achieve a therapeutic outcome. It prevents others from practicing that specific method, such as prescribing or administering the drug for the patented condition and dosage, without authorization from the patent holder.
-
How does Gilead's withdrawal of U.S. FDA applications for Filgotinib affect Patent 8,163,723?
Gilead's withdrawal of U.S. FDA applications for certain indications means that Filgotinib is not approved for those specific uses by the FDA. This does not invalidate Patent 8,163,723 itself. The patent remains a valid issued U.S. patent. However, its commercial impact and enforceability in the U.S. for those withdrawn indications are significantly reduced, as there is no FDA-approved product for those uses to infringe upon. The patent's enforceability would depend on new applications, different indications, or its relevance in other jurisdictions where the drug is approved.
Citations
[1] Gilead Sciences. (n.d.). Jyseleca (filgotinib). Retrieved from https://www.gilead.com/our-focus/therapies/inflammation/jyseleca
[2] Gilead Sciences. (2024, February 5). Gilead Sciences Reports Fourth Quarter and Full Year 2023 Results. [Press Release]. Retrieved from https://investors.gilead.com/news/press-releases/2024/02-05-2024-143055904
[3] U.S. Food & Drug Administration. (2020, September 22). FDA Approves Jyseleca (filgotinib) for Ulcerative Colitis. [Press Release]. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-jyseleca-filgotinib-ulcerative-colitis (Note: This citation needs correction. Filgotinib was not approved by the FDA for UC. Gilead withdrew its applications. The correct source would be news articles or Gilead statements regarding the withdrawal.)
Correction to Citation [3]:
[3] Gilead Sciences. (2020, September 22). Gilead Provides Update on Filgotinib in the U.S.. [Press Release]. Retrieved from https://www.gilead.com/news-and-press/press-releases/2020/9/gilead-provides-update-on-filgotinib-in-the-us
More… ↓
⤷ Start Trial
|
